Clinical Trial Update: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors [Phase 2]

View source ↗

Summary

Phase II trial update of talazoparib in BRCA1/2 wild-type, HER2-negative breast cancer and other solid tumors has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: Melinda Telli | Conditions: Advanced Breast Cancer, HER2/Neu Negative | Phase 2 | Status: COMPLETED | Results posted: 2023-02-21